949P Thermal ablation plus toripalimab in patients with advanced hepatocellular carcinoma: Phase I results from a multicenter, open-label, controlled phase I/II trial (IR11330)

@article{Shi2021949PTA,
  title={949P Thermal ablation plus toripalimab in patients with advanced hepatocellular carcinoma: Phase I results from a multicenter, open-label, controlled phase I/II trial (IR11330)},
  author={Lei Shi and C C Zhou and Xinyao Long and Hongzhao Li and Chen Chen and Changli Peng and Peng-peng Li and Juan Li and Shu-Ling Gu and Baosong Liang and Wangjun Liao},
  journal={Annals of Oncology},
  year={2021}
}
Toripalimab: the First Domestic Anti-Tumor PD-1 Antibody in China
TLDR
It showed a satisfactory anti-tumor effect and long-term survival benefits in Chinese melanoma patients, while the combination of axitinib with toripalimab exhibited an impressive result in metastatic mucosal melanoma.